Decoy Therapeutics Partners with Texas Biomedical Research Institute for Influenza Inhibitor Testing

Decoy Therapeutics and Texas Biomedical Research Institute announce a collaboration to conduct in vitro testing of Decoy's peptide conjugate fusion inhibitors across several influenza strains including H5N1 avian flu. The addition of pan-influenza inhibitors to Salarius' previously designed pan-coronavirus and pan-paramyxovirus inhibitors supports the Company's goal of using its IMP3ACT platform to create a single antiviral inhibitor that is broadly effective against the three viral families that are responsible for the majority of serious seasonal respiratory viral infections. Additionally, Salarius intends to explore the use of these peptides for agricultural health applications such as the treatment of egg-laying poultry flocks.